buble

Talk of biotech market bubble misses the point

The biotech industry is enjoying the strongest IPO market since 2000 with more than 30 new offerings already this year. Our firm alone, Polaris Partners, has seen four successful IPOs in our portfolio, with several more hopefuls on the horizon.

DRI Capital Completes C$600M in Deals in 2012

DRI Capital, a Canadian private equity firm specializing in monetizing royalties it purchases from pharmaceutical and biotechnology companies and others, completed over C$600 million in deals in 2012. Among the firm’s disclosed transactions was the September 2012 acquisition of BENLYSTA royalty rights from Weston, Mass.-based Biogen Idec Ltd. DRI Capital, which celebrates its 20th anniversary in 2013, raised its last partnership, Drug Royalty Fund II, totaling C$700 million, in 2010.

PEHUB Community

Join the 12500 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget